文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-PSMA-I&T治疗前列腺癌腹膜转移

Peritoneal Metastases From Prostate Carcinoma Treated With 177 Lu-PSMA-I&T.
PubMed 文献 · Clin Nucl Med · 2023-01-31

71岁转移性去势抵抗性前列腺癌患者,多线治疗后进展,PSA 260 μg/L,CT示腹水及大网膜、腹膜转移,PSMA PET/CT均阳性;接受4周期177Lu-PSMA-I&T 7.4 GBq(0.2 Ci)治疗,治疗后扫描示所有转移灶靶向良好,4周期后PSA降至44 μ/L,第4周期后4个月一般状况显著改善,PSA降至7.0 μg/L。

要点

  • 转移性去势抵抗性前列腺癌伴腹膜转移,PSMA PET/CT示所有病灶阳性。
  • 接受4周期177Lu-PSMA-I&T 7.4 GBq(0.2 Ci)治疗,治疗后扫描示靶向良好。
  • 4周期后PSA由260 μg/L降至44 μ/L,第4周期后4个月降至7.0 μg/L且一般状况改善。

核心结论

  • 71岁转移性去势抵抗性前列腺癌伴腹膜转移患者接受4周期177Lu-PSMA-I&T治疗后PSA下降、一般状况改善。

研究设计与样本

  • 个案报道:1例71岁男性转移性去势抵抗性前列腺癌患者,多线治疗后进展,PSA 260 μg/L。

主要发现

  • CT示腹水伴大网膜及腹膜转移,PSMA PET/CT示所有病灶阳性。
  • 接受4周期177Lu-PSMA-I&T 7.4 GBq(0.2 Ci)治疗,治疗后扫描示所有转移灶靶向良好。
  • 4周期后PSA降至44 μ/L;第4周期后4个月一般状况显著改善,PSA降至7.0 μg/L。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 71-year-old man was referred for 177 Lu-PSMA therapy. He had metastatic castration-resistant prostate cancer, progressive on several treatment lines, with current PSA 260 μg/L and deteriorating condition. CT showed ascites with omental and peritoneal metastases, all positive on PSMA PET/CT. He was treated with 4 cycles of 7.4 GBq (0.2 Ci) 177 Lu-PSMA-I&T. Posttherapy scans showed good targeting of all metastases. After 4 cycles, PSA had dropped to 44 μ/L. Four months after the fourth cycle, the patients' general condition had significantly improved, and PSA had decreased to 7.0 μg/L.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. van Golen LW, Seijkens TTP, de Feijter JM, et al. Peritoneal Metastases From Prostate Carcinoma Treated With 177 Lu-PSMA-I&T. Clin Nucl Med. 2023. PMID: 36716524. doi:10.1097/RLU.0000000000004577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。